Published: 19. April, 2021
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1…
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2021. The company is on track with Q1 activities, has initiated the bioavailability trial 0204 and was awarded best medical IPO in 2020 in the Nordics.
“The first quarter of 2021 was the follow up from many of the initiated activities in Q4’2021 and earlier years – in particular the very important top line result of the Registry Safety Study (0203) and the initiation of trail 0204. We tend to forget that safety is actually often more important than efficacy when it comes to children, and the study 0203 results confirms that CT001 could be much easier to apply in any hospital setting as ‘No serious adverse events were reported’ – the outlook is really positive for CT001. We have 2 major milestones left for 2021 – the results of trial 0204 and trail 0206 – this will be an exciting year.” Says Jes Trygved, CEO
